Sigilon Therapeutics Inc

SGTX | $22.47 -2.56% 0.0% 0

(0.0% 1d) (0.0% 1m) (152.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (32.61% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 56,500,770
https://sigilon.com
Sec Filling | Patents | 2021 employees

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

diabetic diabetes ceiling t-cell

add to watch list Paper trade email alert is off

4D Molecular Therapeutics Inc

FDMT M | $24.99 0.73% 38K

Health Technology

(0.0% 1d) (-26.2% 1m) (18.0% 1y) (0.0% 2d) (-6.0% 3d) (-0.7% 7d) (16.69% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 1,278,425,225
https://www.4dmoleculartherapeutics.com
Sec Filling | Patents | 83 employees

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

urea ceiling education antibody gene therapies t-cell

add to watch list Paper trade email alert is off

Vivos Therapeutics Inc

VVOS | $2.65 8.9K

Health Technology

(0.0% 1d) (-41.8% 1m) (648.8% 1y) (0.0% 2d) (0.4% 3d) (-2.6% 7d) (14.89% volume)
Earnings Calendar: 2022-11-28
Market Cap: $ 7,903,016
https://www.vivoslife.com
Sec Filling | Patents | 115 employees

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Combining technologies and protocols that alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. Sales of the Vivos System are driven by the Vivos Integrated Practice (VIP) program, which offers dentists training and value-added services in connection with their use of the Vivos System.

treatment education

add to watch list Paper trade email alert is off

Virios Therapeutics Inc

VIRI | $0.469 8.82% 120K

Health Technology

(0.0% 1d) (-8.5% 1m) (-55.7% 1y) (0.0% 2d) (0.0% 3d) (-2.3% 7d) (9.52% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 9,031,972
https://www.virios.com
Sec Filling | Patents | 3 employees

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ('IBS'), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ('IMC-1'), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

fibromyalgia education antiviral rsv

add to watch list Paper trade email alert is off